Advancing a gene editing program toward clinical use requires far more than demonstrating editing efficiency. From the earliest stages of development, teams must consider manufacturing readiness and regulatory compliance.

Clinical execution involves meeting cGMP standards, establishing phase‑appropriate quality systems, robust documentation and the ability to withstand increasing regulatory scrutiny. Common pain points include

• Defining starting-material controls for gRNAs and vectors
• Demonstrating process reliability at increasing scales
• Assembling audit-ready documentation swiftly to meet clinical timelines

Addressing these challenges early can make the difference between momentum and delay as programs move toward IND or CTA submission.

Phase Appropriate Manufacturing and Regulatory Support

As gene editing programs progress from discovery to the clinic, manufacturing and regulatory requirements evolve rapidly. Having the right level of support at each phase helps ensure continuity, compliance, and confidence as programs move forward.

cGMP gRNA Manufacturing to Accelerate Gene Editing Programs

For customers looking to accelerate their therapeutic gene editing program from discovery to clinical trials, IDT and Aldevron offer Engineering Run and full cGMP-compliant guide RNA (gRNA) manufacturing and sequencing services. Backed by comprehensive documentation, these services support regulatory compliance while helping accelerate IND/CTA filings without compromising quality, traceability, or control.

Supporting Clinical and Commercial Gene Editing at Scale

Aldevron supports gene editing programs with cGMP-compliant production, rigorous quality control and adherence to clinical trial standards. This approach minimizes variability while ensuring scalability, whether programs are advancing through clinical development or preparing for commercialization.

With experience supported by 1,100+ clinical trials and 15 commercial programs, Aldevron helps teams navigate complex regulatory landscapes and provides scalable manufacturing solutions that meet both clinical and commercial needs.

Preparing for clinical execution starts long before the clinic. Learn how phase‑appropriate manufacturing and regulatory strategies can help de‑risk your gene editing program and accelerate your path to the clinic.